PCVX Stock Forecast: Vaxcyte, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$55
−5.09% on the day

The 11 Wall Street analysts covering Vaxcyte, Inc. hold a median 12-month price target of $121 — +118.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 46 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$8.8B
Ticker Nerd rank
46/ 100
Median analyst target
$121
Analysts covering
11
Revenue$0.0
Operating income−$302.8M
Net income−$284.3M
Free cash flow−$237.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.6%
1M
−16.4%
YTD
+20.0%
1Y
+16.2%
From 52W high
−25.0%
From 52W low
+28.6%
$43
$74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Vaxcyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
46/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
85
Value
85
Volatility
77
Quality
59
Revisions
55
Accruals
49
Growth
20
Issuance
15

Momentum (85): The shares have been drifting up relative to others.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PCVX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PCVX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Jan 26Apr 26Jul 26Oct 26PCVXHigh $163Median $121Low $75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
10
Buy
1
Hold
0
Sell
$75
Low
$121
Median
$163
High

The green dot is the last close — the median target sits +118.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
12 Oct 2026Cantor FitzgeraldReiteratesOverweight$120
5 Oct 2026BTIGReiteratesBuy$89
5 Oct 2026GuggenheimMaintainsBuy$116 → $125
5 Oct 2026NeedhamMaintainsBuy$110 → $122
28 Sept 2026B of A SecuritiesMaintainsBuy$133 → $130
25 Sept 2026NeedhamReiteratesBuy$110
26 Feb 2026BTIGMaintainsBuy$85 → $89
2 Feb 2026GuggenheimReiteratesBuy—
10 Nov 2025BTIGReiteratesBuy—
16 Oct 2025BTIGMaintainsBuy—
12 Sept 2025Goldman SachsInitiatesNeutral—
22 Apr 2025Cantor FitzgeraldInitiatesOverweight—
8 Apr 2025NeedhamReiteratesBuy—
1 Apr 2025B of A SecuritiesMaintainsBuy—
1 Apr 2025Goldman SachsMaintainsBuy—
1 Apr 2025NeedhamMaintainsBuy—
12 Mar 2025GuggenheimReiteratesBuy—
26 Feb 2025GuggenheimReiteratesBuy—
26 Feb 2025NeedhamReiteratesBuy—
24 Feb 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PCVX.

Market Radar

This page is one stock. Monday covers all of them.

PCVX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PCVX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Vaxcyte, Inc. returned +16.2% against +6.9% for the S&P 500, dividends included.

PCVX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26PCVXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PCVX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
3.3×

Cheaper than 28% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−42.7%

Higher than 24% of US stocks

Return on assets
−25.0%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vaxcyte, Inc. has a market value of $8.8B and an enterprise value of $7.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$1.1B.

  • Free cash flow in the twelve months to 30 June 2026: −$921.1M.

  • Shares outstanding: 144.8M.

  • Vaxcyte, Inc. employs 507 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

PCVX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PCVXVaxcyte, Inc.$8.8B46
MDGLMadrigal Pharmaceuticals, Inc.$8.7B79
SYRESpyre Therapeutics, Inc.$8.6B33
KRYSKrystal Biotech, Inc.$9.1B83
PRAXPraxis Precision Medicines, Inc.$8.2B34
SMMTSummit Therapeutics, Inc.$7.9B36
KYMRKymera Therapeutics, Inc.$9.6B65

Take a look at PCVX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Vaxcyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PCVX

What is the PCVX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Vaxcyte, Inc. have a median 12-month price target of $121, with estimates ranging from $75 to $163. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PCVX stock a buy right now?

Of the 11 analysts covering Vaxcyte, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vaxcyte, Inc. 46 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PCVX?

As at 21 Nov 2026, Vaxcyte, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (85 of 100).

Will PCVX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +118.5% from the last close, and Ticker Nerd's factor model ranks Vaxcyte, Inc. 46 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PCVX stock forecast for 2030?

No analyst covering Vaxcyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $163 over the next 12 months.

How has PCVX stock performed over the past year?

Vaxcyte, Inc. returned +16.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vaxcyte, Inc. do?

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases. The company uses its proprietary cell-free protein synthesis platform to design and produce optimized protein carriers and antigens, supporting the creation of conjugate and protein-based vaccine candidates.

Company

About Vaxcyte, Inc.

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing next-generation vaccines for bacterial infectious diseases. The company uses its proprietary cell-free protein synthesis platform to design and produce optimized protein carriers and antigens, supporting the creation of conjugate and protein-based vaccine candidates. Its current pipeline centers on pneumococcal programs aimed at preventing invasive pneumococcal disease, along with additional candidates targeting other serious bacterial conditions. Vaxcyte Inc. operates in the biotechnology and infectious disease markets, where its work addresses areas with significant unmet medical need. Based in San Carlos, California, the company is known for its emphasis on broad-spectrum vaccine design and advanced manufacturing methods that differ from conventional cell-based approaches.

CEO Mr. Grant E. Pickering M.B.A. · 507 employees · United States · https://vaxcyte.com